@jsmkhoo@RossMaltz I would be careful what you wish for @jsmkhoo you may end up with a new project or @RossMaltz will tell you to write your current manuscripts 🤣
It has been an amazing 3 years @RossMaltz. I can’t believe it is an end of an era. You have taught me so much and I still have so much to learn from you. I will make a list of things you still have to teach me for our next research meeting.
So sad to see my mentee, GI fellow, researcher, and friend @SamPaglinco graduate and move on to great things. I know we will keep in touch especially since we have a research meeting on July 2nd. Picture from a card she gave me. A picture of us holding her research award.
State and federal lawmakers need to stop insurance companies and PBMs from practicing medicine without a license. Make no mistake, insurers, PBMs and Rx companies are all complicit. Where’s the transparency?
This week Cigna said it would be spending $11.3 billion not to lower premiums, deductibles, or improve health care for its policy holders, but to buy back its stock to make its executives and stockholders even richer. This is what a corrupt & broken health care system looks like.
Everyone doubted us. Said we couldn't impact an industry that no one trusts. Here we are less than 2 years later announcing we are adding ONE THOUSAND+ new drugs, bringing our total to more than 2,200 !!!
It's time to check again to see if https://t.co/HSbdDXpdy9 carries your meds !
Thank you to everyone who believes in us !
This editorial is🌟in many ways
🫶🏾Partnering w @ReezwanaCMD who was my GI fellow & now an IBD colleague💜
🔎@tinahamd & al. work #RectalUrgency
📈16-20% of #IBD
⬆️ w active🔥
⬇️QOL, sleep, work
🤝Should be a 🎯 in pt-centered Q & approach to IBD Rx
🔗 https://t.co/3JRtMYYv3l
Losses of exclusivity for biologics and intro of biosimilars have increased in the past three years, with brand sales of those products dropping by $33Bn over the past five years compared to $4Bn over the prior five years and reflecting a growing role for biosimilars.
It is really hard to do proactive TDM with adalimumab. (Since it requires an extra trip to the lab right before an injection).
This is an important consideration when doing shared decision with families on initiating infliximab or adalimumab.
@andrewbgrossman#ICNCCF23
“Only” 10 years old yet possessing poise, passion and leadership skills surpassing those far older: Samantha and her wonderful #PedsGI doc @DrPasternak_IBD taught us the power of what our children can do and teach us at #ICNCC23F@ImproveCareNow
Learning about how early, appropriate use of surgery in #IBD is an important tool from @MLongMD, so essential to remember and check out the pediatric IBD & surgery #SDM tool and study from @ImproveCareNow! @ICNPatients#ICNCCF23
Learn more here!: https://t.co/0fbQvf7X8z
Confused 🤷🏻♀️🤷🏻♂️on all of the adalimumab biosimilars and the difference among them?!
Me too!
I can’t keep the differences straight. Below is an awesome resource for information on adalimumab biosimilars!
#ICNCCF23
We have work to do 💪🏼to close the gaps of inequities so ALL children get the care they deserve. Addressing social determinants of health is important.
#ICNCCF23
Ongoing call to action for our community to meaningfully and sustainably address inequities in pediatric #IBD for *all* our kids to have accessible, equitable, interdisciplinary, & excellent care @ImproveCareNow@ICNPatients#ICNCCF23